For patients with diabetes, semaglutide use is associated with ... Cai et al, Conflicting Results—Need for More Transparent and Reproducible Research, JAMA Ophthalmology (2025).

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...

The FDA and drugmaker Novo Nordisk on Monday warned that counterfeit vials of Ozempic® (semaglutide) are being sold to consumers and may cause a safety risk. Novo Nordisk cautions pharmacies and ...

Using real-world data from over 300,000 cases, scientists uncovered a significant link between semaglutide and reported vision problems—raising new concerns about the safety profile of this ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...